Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

As the number of highly potent oral solid dose (HPOSD) drugs in development and on the market increases, so are regulator’s expectations regarding their safe manufacture. In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Learn about

  • Concepts and advice that improve HPOSD cGMP manufacturing compliance.
  • Overview of regulatory models governing HPOSD manufacturing.
  • Pfizer CentreOne’s integrated approach to HPOSD manufacturing safety.

You can download the full white paper by completing the form below.

Pfizer CentreOne would like to send you information which we believe may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.